Cambricon
688256
Ping An Insurance
601318
China Vanke Co.,Ltd.
000002
4
Kweichow Moutai
600519
5
Semiconductor Manufacturing International Corporation
688981
CN Stock MarketDetailed Quotes
688062 Mabwell
- 15.60
- -0.18-1.14%
Market Closed Jan 23 15:00 CST
6.23BMarket Cap-5.80P/E (TTM)
16.12High15.60Low40.91KlotVolume15.93Open15.78Pre Close65.06MTurnover2.00%Turnover RatioLossP/E (Static)399.60MShares37.0052wk High3.25P/B3.19BFloat Cap15.3652wk Low18.94Limit Up204.17MShs Float37.00Historical High12.62Limit Down3.30%Amplitude12.96Historical Low--Dividend TTM15.90Avg Price20.17KlotAsk--Div YieldTTM100Lot Size18.11KlotBid
Mabwell News
Maiwei Biotech: Maiwei Biotech\'s announcement on continuing to use some temporarily idle funds raised for cash management
Maiwei Biotech: Announcement of Resolutions of the 15th Meeting of the 2nd Supervisory Board of Maiwei Biotech
Maiwei Biology: Opinions of Haitong Securities Co., Ltd. on the continued use of some temporarily idle funds raised by Maiwei (Shanghai) Biotechnology Co., Ltd. for cash management
Haitong Securities Co., Ltd.\'s verification opinion on Maiwei (Shanghai) Biotechnology Co., Ltd. continuing to use some temporarily idle funds raised for cash management
Maiwei Biotech\'s announcement on continuing to use some temporarily idle funds raised for cash management
Announcement of Resolutions of the 15th Meeting of the 2nd Supervisory Board of Maiwei Biotech
Maiwei Biotech 2024 Annual Results Forecast
Maiwei Biotech: Maiwei Biotech voluntarily disclosed the announcement that 9MW2821 combined with treprimab was included in the public list of breakthrough treatment varieties for first-line treatment of urothelial cancer
Maiwei Biotech voluntarily disclosed an announcement on the inclusion of 9MW2821 and treprilizumab in the first-line treatment of urothelial cancer in the public list of breakthrough treatment varieties
Maiwei Biotech: Announcement on the submission of an application for the issuance and listing of H shares to the Hong Kong Stock Exchange and publication of application materials
Maiwei Biotech: Maiwei Biotech\'s announcement on opening a special fund raising account and signing a tripartite supervisory agreement for fund raising special account storage
Announcement of Maiwei Biotech\'s submission of an application for the issuance and listing of H shares to the Hong Kong Stock Exchange and publication of application materials
Announcement of Maiwei Biotech on opening a special fund-raising account and signing a tripartite supervisory agreement for fund-raising special account storage
Maiwei Biotech Investor Relations Activity Record List (December 1, 2024)
Legal Opinion of Beijing Zhide (Shanghai) Law Firm on the 2024 Fourth Extraordinary General Meeting of Shareholders of Maiwei (Shanghai) Biotechnology Co., Ltd.
Announcement of Resolutions of the 2024 Fourth Extraordinary General Meeting of Shareholders of Maiwei Biotech
Maiwei Biotech: Meeting materials for the 2024 4th Extraordinary General Meeting of Shareholders of Maiwei Biotech
Maiwei Biotech 2024 Fourth Extraordinary General Meeting of Shareholders Meeting Information
Maiwei Biology: “Working Rules of the Remuneration and Assessment Committee of the Board of Directors of Maiwei (Shanghai) Biotechnology Co., Ltd.” (Draft)
Maiwei Biotech: Miwei Biotech\'s announcement on revising the equity incentive plan formulated before listing